Search

Calmare NJ USA

Tag

scrambler therapy study

Medscape reports on another positive clinical trial using Calmare for cancer pain

medscapeAnother Calmare Therapy clinical trial, conducted with people battling neuropathic pain as a result of chemotherapy treatment, has again shown  positive patient outcomes (significant lessening of pain) according to a new report published this week by Medscape, an affiliate of WebMD. (You have to register to read the article, but the process is free, quick and easy).

clinical trialCalmare Trial Key Points / Excerpts:

  • Scrambler therapy was not originally developed for the treatment of cancer-related neuropathic pain. Rather, it was developed for chronic pain and, indeed, has been used in many patients with noncancer-related pain, including low back pain.
  • Regardless of the type of neuropathic pain being treated, scores on the 11-point Numerical Rating Scale (NRS) decreased significantly from baseline to 1-month follow-up (P < .001).
  • The need for ‘rescue opioids’ dropped from a baseline dose of 5 mg to 0 mg at the end of the study.
  • No adverse side effects (“events”) that could have been associated with the therapy were reported.
  • A research team from the Massey Cancer Center at Virginia Commonwealth University in Richmond reported similar findings using the same cutaneous electro-stimulation device (scrambler therapy) for CIPN (J Pain Symptom Manage. 2010;40:883-891).
  • Some patients relapsed, but re-treatment and maintenance therapy (booster treatments) provided relief and, again, no adverse effects from treatment were observed.
  • Charles Loprinzi, MD, PhD, from the Mayo Clinic in Rochester, Minnesota, and colleagues conducted a trial with 37 CIPN patients and achieved similar study outcomes (Support Care Cancer. 2015 23:943-951).
  • Dr. Loprinzi stated that people have been slow to explore scrambler therapy use because “it sounds too good to be true…” He also reported to Medscape that efforts to conduct larger trials are ongoing, but it takes time and money to perform these trials.

The European Journal of Oncology Nursing also published an abstract of the study reported by Medscape.


New Brigham Young University research team to study Calmare scrambler therapy

trialsAdd another upcoming university-based, clinical research study about Calmare scrambler therapy to the list:

In addition to Johns Hopkins, Mayo Clinic, Massey Cancer Institute and others, BYU researchers will be conducting its own scrambler therapy study.

Dr. David Busath, heading up the research at Brigham Young University, stated, “I think the fooling the brain idea is a 1024px-BYU_Medallion_Logo.svglegitimate one…we’re convincing the brain in one area that this other area shouldn’t be hyperactive after all.”

Dr. Busath’s study protocol will consist of taking a patient  MRI for 20 minutes, then performing Calmare for 30 minutes, followed by another MRI.

Calmare provider and pain therapist Erick Bingham, not affiliated with the BYU study, stated in the article that the successful outcome for scrambler therapy patients depends on how the individual reacts after the very first treatment and believes patient response early on can be a predictor of the outcome. He says that 80 percent of the time, if the patient sustains a reduction in pain after that first treatment, they’re going to be a good candidate.

Dr. Bingham accurately noted that some patients will require periodic booster treatments while others remain pain-free with no need for future treatment.

Read the full article here

BYU scrambler therapy study candidates must have constant sharp pain in the hands or feet and not be on any anti-convulsant medication. Additionally, participants cannot have stents, pacemakers or other implants that would interfere with an MRI scan. Those wishing to apply for the two-phase study can contact Dr. Busath’s office at 801-422-8753.

Blog at WordPress.com.

Up ↑

%d bloggers like this: